Target identification · 中文
How we identify
targets
The hardest decision in a drug program is which target to pursue · we make it from human biology
Why it decides everything
Most drugs fail on the target
not the molecule
A perfect molecule against the wrong target still fails. So we treat target identification as a first-class discipline, and we anchor it in human biology — what patient data and human genetics say actually drives the disease — rather than in what is already being drugged. We look across diseases, not one at a time, and we work drug-blind: a target has to earn its place on the evidence, not on the fact that someone else is already chasing it.
From evidence to a shortlist
Many candidates in
a few credible targets out
We start from human-genetic and patient evidence, rank candidates by how causally they drive the disease, and keep only the ones that clear every gate that matters.
A prioritized target then enters the design engine — see how we design against it →
What makes a target credible
Five gates every time
Causal human genetics
Human genetic evidence that the gene actually drives the disease — not just correlates with it.
Expression in disease tissue
Present in the right cells and the right compartment, where a medicine could act.
Mechanistic plausibility
A credible biological path from engaging the target to a benefit for patients.
Tractable with our modality
Reachable by a cyclic-peptide / macrocycle — including hard interfaces others set aside.
Novel & differentiated
Distinct from crowded, me-too targets, with clear freedom to develop.
Shared across diseases
Where a single target reaches more than one immune-mediated disease, its value compounds.